Danaher Accelerates CRISPR Breakthrough Using DBS, Treats Infant in Record Time
SHERIDAN, WYOMING – May 17, 2025 – Danaher Corporation has achieved a historic milestone in genomic medicine, enabling the development and delivery of the world’s first personalized mRNA-based CRISPR therapy for an infant with a life-threatening genetic disorder—in under six months. Powered by the Danaher Business System (DBS), this breakthrough exemplifies how disciplined innovation and cross-company collaboration can dramatically accelerate biopharmaceutical timelines and patient impact.
Compressing an 18-Month Timeline into Six